Cardiac myosin activation in the treatment of congestive heart failure: New therapeutic options and review of literature

Abstract

Congestive heart failure (HF) remains a major cause of cardiac-related morbidity and mortality, despite major therapeutic advancements. A newer class of medications has recently been developed which targets the root cause of HF, which is reduced myocardial contractility. This article aims to highlight the cardiac myosin activator class of drugs and the trials to date highlighting their effects on HF outcomes.

Keywords

• heart failure
• myosin
• omecamtiv mecarbil